FrancophonIA/ELRC3.0 huggingface dataset:
English: The long-term consequences of continuing alirocumab treatment in the presence of ADA are unknown.
Slovenian: Dolgoročne posledice nadaljevanja zdravljenja z alirokumabom v prisotnosti ADA niso znane.
English: • alcohol wipes
Slovenian: • alkoholne zložence
English: Press the yellow safety cover on your skin at roughly a 90° angle.
Slovenian: Pritisnite rumeni varnostni ščitnik ob kožo pod kotom približno 90°.
English:  Check if the window has turned yellow, before removing the pen.
Slovenian:  Preverite, da je okence postalo rumeno, preden peresnik odstranite.
English: Table 3: Efficacy of Alirocumab in ODYSSEY OUTCOMES (Overall Population)
Slovenian: Preglednica 3: Učinkovitost alirokumaba v študiji ODYSSEY OUTCOMES (celotna populacija)
English: ALTERNATIVE study
Slovenian: Študija ALTERNATIVE
English: Immunogenicity/ Anti-drug-antibodies (ADA)
Slovenian: Imunogenost/protitelesa proti zdravilu (ADA)
English:  Prepare the injection site.
Slovenian:  Pripravite mesto za injiciranje.
English: Praluent is not recommended for children and adolescents under 18 years old.
Slovenian: Zdravilo Praluent ni priporočljivo za otroke in mladostnike, mlajše od 18 let.
English: • Do not remove the syringe until it is completely empty.
Slovenian: • Ne odstranite brizge, dokler ni popolnoma prazna.
English: <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Slovenian: občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in ni znano (ni mogoče oceniti na podlagi podatkov, ki so na voljo).
English: HIGH FH study
Slovenian: Študija HIGH FH
English: The observed cases of pruritus were typically mild and transient.
Slovenian: Opaženi primeri srbenja so bili po navadi blagi in prehodni.
English: There are no data on adverse effects on fertility in humans.
Slovenian: Ni podatkov o neželenih učinkih na plodnost pri človeku.
English: SANOFI CHIMIE 9 Quai Jules Guesde 94403 Vitry-sur-Seine France
Slovenian: SANOFI CHIMIE 9 Quai Jules Guesde 94403 Vitry-sur-Seine Francija
English: The safety profile in ODYSSEY OUTCOMES was consistent with the overall safety profile described in the phase 3 controlled trials.
Slovenian: Varnost v študiji ODYSSEY OUTCOMES se je ujemala s celokupnimi značilnostmi varnosti, opisanimi v kontroliranih preskušanjih 3. faze.
English: This leads to the increased target-mediated clearance and reduced systemic exposure of alirocumab.
Slovenian: Posledici sta večji ciljno posredovani očistek in manjša sistemska izpostavljenost alirokumabu.
English: If you stop using Praluent, your cholesterol levels can increase.
Slovenian: Če prenehate uporabljati zdravilo Praluent, se vam koncentracija holesterola lahko zviša.
English: • The medicine is injected under your skin and can be given by yourself or someone else (caregiver).
Slovenian: • Zdravilo se injicira pod kožo; injicirate si ga lahko sami, ali vam ga injicira kdo drug (negovalec).
English: What Praluent is and what it is used for 2.
Slovenian: Kaj je zdravilo Praluent in za kaj ga uporabljamo 2.
English: For allergic reactions that may occur while taking Praluent, see section 4.
Slovenian: Za alergijske reakcije, ki se lahko pojavijo med uporabo zdravila Praluent, glejte poglavje 4.
English: In controlled clinical studies, no safety issues were identified with more frequent dosing than the recommended every 2 week dosing schedule.
Slovenian: V kontroliranih kliničnih študijah niso ugotovili nobenih težav z varnostjo, če je bilo odmerjanje pogostejše od priporočenega razporeda na 2 tedna.
English: There were no significant differences observed in safety and efficacy with increasing age.
Slovenian: Z naraščajočo starostjo niso opazili bistvenih razlik v varnosti in učinkovitosti.
English: • Do not use any area near a visible vein.
Slovenian: • Ne uporabljajte predelov, ki so blizu vidnih žil.
English: The results are presented in Table 3.
Slovenian: Rezultati so prikazani v preglednici 3.
English: When to inject
Slovenian: Kdaj injicirati
English: If signs or symptoms of serious allergic reactions occur, treatment with Praluent must be discontinued and appropriate symptomatic treatment initiated (see section 4.3).
Slovenian: Če se pojavijo znaki ali simptomi resne alergijske reakcije, je treba zdravljenje z zdravilom Praluent končati in uvesti ustrezno simptomatsko zdravljenje (glejte poglavje 4.3).
English: Since the effects of alirocumab on the breast-fed infant are unknown, a decision should be made whether to discontinue nursing or to discontinue Praluent during this period.
Slovenian: Ker učinki alirokumaba na dojene dojenčke niso znani, se je treba odločiti bodisi za prekinitev dojenja bodisi za prekinitev uporabe zdravila Praluent med tem obdobjem.
English: FH I and FH II studies
Slovenian: Študiji FH I in FH II
English: It is not known whether alirocumab is excreted in human milk.
Slovenian: Ni znano, ali se alirokumab izloča v materinem mleku.
English: Human immunoglobulin G (IgG) is excreted in human milk, in particular in colostrum; the use of Praluent is not recommended in breast-feeding women during this period.
Slovenian: Človeški immunoglobulin G (IgG) se izloča v materinem mleku, še zlasti v kolostrumu; uporaba zdravila Praluent pri doječih ženskah ni priporočljiva.
English: The use of Praluent is not recommended during pregnancy unless the clinical condition of the woman requires treatment with alirocumab.
Slovenian: Zdravila Praluent ni priporočljivo uporabljati med nosečnostjo, razen če klinično stanje ženske zahteva zdravljenje z alirokumabom.
English: Two studies were conducted in patients who were not concomitantly treated with a statin, including one study in patients with documented statin intolerance.
Slovenian: Dve študiji so izvedli pri bolnikih, ki sočasno niso jemali statina; ena od njiju je bila študija pri bolnikih z dokumentirano intoleranco za statine.
English: Yellow safety cover Needle inside
Slovenian: Rumeni varnostni ščitnik Igla v notranjosti
English: COMBO II study
Slovenian: Študija COMBO II
English: The lipid-lowering effect of alirocumab was observed within 15 days after the first dose reaching maximum effect at approximately 4 weeks.
Slovenian: Učinek alirokumaba na znižanje lipidov so opazili v 15 dneh po prvem odmerku, največji učinek pa je bil dosežen po približno 4 tednih.
English: Name and address of the manufacturers of the biological active substance
Slovenian: Ime in naslov izdelovalcev biološke aktivne učinkovine
English: General allergic reactions
Slovenian: Splošne alergijske reakcije
English: • Do not use if the window appears solid yellow (see picture B).
Slovenian: • Ne uporabite, če je okence popolnoma rumeno (glejte sliko B).
English: MONO study
Slovenian: Študija MONO
English: All-cause mortality
Slovenian: Umrljivost zaradi vseh vzrokov
English: There were no adverse effects on fetal growth or development in rats or monkeys.
Slovenian: Neželenih učinkov na rast ali razvoj ploda pri podganah in opicah ni bilo.
English: The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports.
Slovenian: Pogostnosti neželenih učinkov, opisanih v obdobju po prihodu zdravila na trg, ni mogoče ugotoviti, ker so zbrani na podlagi spontanih poročil.
English: • “Bad” cholesterol is normally removed from your blood by binding to specific “receptors” (docking stations) in your liver.
Slovenian: • "Slabi" holesterol se običajno odstranjuje iz krvi z vezavo na specifične "receptorje" (vezavna mesta) v jetrih.
English: This is because there is no experience of using the medicine in these age groups.
Slovenian: S tem zdravilom namreč v teh dveh starostnih skupinah ni izkušenj.
English: There was no other evidence of alirocumab-related immune dysfunction in the offspring.
Slovenian: Drugih dokazov z alirokumabom povezane imunske disfunkcije pri mladičih ni bilo.
English: Not all presentations and pack sizes may be marketed.
Slovenian: Na trgu morda ni vseh navedenih oblik in pakiranj.
English: • Press and firmly hold the pen against your body until the yellow safety cover is no longer visible.
Slovenian: • Pritisnite peresnik ob telo in ga trdno držite, dokler rumeni varnostni ščitnik ni več viden.
English: Alirocumab binds to PCSK9.
Slovenian: Alirokumab se veže na PCSK9.
English: Two elimination phases were observed for alirocumab.
Slovenian: Za alirokumab so opažali dve fazi izločanja.
English: • a puncture-resistant container (see Step B, 8).
Slovenian: • vsebnik za ostre odpadke (glejte korak B, 8).
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Slovenian: Če ste noseči ali dojite, menite, da ste noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden uporabite to zdravilo.
English: This did not translate into a clinically meaningful difference in LDL-C lowering.
Slovenian: To ni povzročilo klinično pomembne razlike v znižanju h-LDL.
English: • a puncture-resistant container (see Step B, 6).
Slovenian: • vsebnik za ostre odpadke (glejte korak B, 6).
English: Your doctor will check your cholesterol levels and may adjust the dose (up or down) during treatment.
Slovenian: Zdravnik vam bo kontroliral koncentracijo holesterola in vam lahko med zdravljenjem odmerek prilagodi (poveča ali zmanjša).
English: Excluding injection site reactions (ISRs) that occurred after these placebo injections, the frequency of ISRs was 11.8%.
Slovenian: Izključujoč reakcije na mestu injiciranja, ki so se pojavile po teh injekcijah placeba, je bila pogostnost reakcij na mestu injiciranja 11,8 %.
English: What you need to know before you use Praluent 3.
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo Praluent 3.
English: FHI and FHII (N=732)
Slovenian: FHI in FHII (N = 732)
English: • If needed, pinch the skin to make sure the injection site is firm.
Slovenian: • Če je treba, stisnite kožo v kožno gubo, da bo mesto injiciranja trdno.
English: • PCSK9 lowers the number of these receptors in the liver - this causes your “bad” cholesterol to be higher than it should.
Slovenian: • PCSK9 zmanjša število teh receptorjev v jetrih in tako povzroči, da je "slabega" holesterola več, kot bi ga smelo biti.
English: There is no specific treatment for Praluent overdose.
Slovenian: Specifičnega zdravljenja prevelikega odmerjanja zdravila Praluent ni.
English: The only adverse reaction identified in ODYSSEY OUTCOMES (a long-term cardiovascular outcome trial) was injection site reaction.
Slovenian: Edini neželeni učinek, ugotovljen v študiji ODYSSEY OUTCOMES (dolgoročno ugotavljanje srčno-žilnih izidov), je bila reakcija na mestu injiciranja.
English: • Do not use skin that is tender, hard, red or hot.
Slovenian: • Ne injicirajte v kožo, ki je občutljiva, zatrdela, pordela ali vroča.
English: Based on a population pharmacokinetic analysis, age was associated with a small difference in alirocumab exposure at steady state, with no impact on efficacy or safety.
Slovenian: Na podlagi populacijske farmakokinetične analize je starost povezana z majhno razliko v izpostavljenosti alirokumabu v stanju dinamičnega ravnovesja, brez vpliva na učinkovitost ali varnost.
English: The distribution of body weight and age, two covariates impacting alirocumab exposure, were different among renal function categories and most likely explain the observed pharmacokinetic differences.
Slovenian: Porazdelitev telesne mase in starosti - ki obe vplivata na izpostavljenost alirokumabu - sta se med obema kategorijama delovanja ledvic razlikovali; to najverjetneje pojasni opažene farmakokinetične razlike.
English: The Kaplan-Meier estimates of the cumulative incidence of the primary endpoint for the overall patient population over time are presented in Figure 1.
Slovenian: Kaplan-Meierjeve ocene kumulativne pojavnosti primarnega izida v celotni populaciji skozi čas so prikazane na Sliki 1.
English: If a dose is missed, the patient should administer the injection as soon as possible and thereafter resume treatment on the original schedule.
Slovenian: Če bolnik izpusti odmerek, si mora injekcijo dati čim prej, nato pa nadaljevati zdravljenje po prvotnem razporedu.
English: The fluctuations between Cmax and Ctrough were higher for the every 4 weeks dosage regimen.
Slovenian: Nihanja med Cmax in Ctrough so bila s shemo na 4 tedne večja.
English: Frequencies for all adverse reactions identified from clinical trials have been calculated based on their incidence in pooled phase 3 clinical trials.
Slovenian: Pogostnosti vseh neželenih učinkov, ugotovljenih v kliničnih preskušanjih, so bile izračunane na podlagi njihove pojavnosti v kliničnih preskušanjih 3. faze kumulativno.
English: If you have questions, ask your doctor, pharmacist or nurse or call the sanofi-aventis number on the package leaflet.
Slovenian: Če imate vprašanja, se obrnite na zdravnika, farmacevta ali medicinsko sestro, ali pokličite telefonsko številko družbe sanofi-aventis, ki je navedena na navodilu za uporabo.
English: Three of the ten studies were conducted exclusively in patients with heterozygous familial hypercholesterolaemia (heFH).
Slovenian: Tri od desetih študij so bile izvedene izključno pri bolnikih s heterozigotno familiarno hiperholesterolemijo (heFH).
English: Release the button immediately
Slovenian: Gumb takoj izpustite klik
English: Figure 1 Primary Composite Endpoint Cumulative Incidence Over 4 Years in ODYSSEY OUTCOMES
Slovenian: Slika 1: Kumulativna pojavnost primarnega sestavljenega izida v 4-letnem obdobju v študiji ODYSSEY OUTCOMES
English: Do not stop using Praluent without talking with your doctor.
Slovenian: Ne prenehajte uporabljati zdravila Praluent, ne da bi se posvetovali z zdravnikom.
English: Frequency categories are defined as: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to
Slovenian: Kategorije pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10),
English: Although no safety issues were observed in patients over 75 years of age, data are limited in this age group.
Slovenian: Pri bolnikih, starejših od 75 let, niso opazili težav z varnostjo, vendar je podatkov za to starostno skupino malo.
English: Alirocumab is expected to degrade to small peptides and individual amino acids.
Slovenian: Pričakovati je, da se alirokumab razgradi v majhne peptide in posamezne aminokisline.
English: Praluent has no or negligible influence on the ability to drive and use machines.
Slovenian: Zdravilo Praluent nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
English: • If you see any blood, press a cotton ball or gauze on the site until the bleeding stops.
Slovenian: • Če se pojavi kri, na mesto injiciranja pritisnite kosem vate ali gazo, dokler se krvavitev ne ustavi.
English: Although similar efficacy was observed in patients over 75 years, data are limited in this age group.
Slovenian: Med bolniki, starejšimi od 75 let, je bila učinkovitost podobna, vendar je podatkov za to starostno skupino malo.
English: If the solution is discoloured or contains visible particulate matter, the solution should not be used.
Slovenian: Če je raztopina spremenjene barve ali vsebuje vidne delce, se je ne sme uporabiti.
English: Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration).
Slovenian: Koncentracijo lipidov je mogoče oceniti 4 do 8 tedne po uvedbi ali titriranju zdravila in odmerek je tedaj mogoče ustrezno prilagoditi (povečati ali zmanjšati).
English: Praluent should not be injected into areas of active skin disease or injury such as sunburns, skin rashes, inflammation, or skin infections.
Slovenian: Zdravila Praluent se ne sme injicirati v predele aktivne kožne bolezni ali poškodbe, npr. sončnih opeklin, izpuščaja, vnetja ali okužb kože.
English: • PCSK9 is a protein secreted by liver cells.
Slovenian: • PCSK9 je beljakovina, ki jo izločajo jetrne celice.
English: Limited data are available in patients with severe renal impairment; in these patients the exposure to alirocumab was approximately 2-fold higher compared with subjects with normal renal function.
Slovenian: Podatkov o bolnikih s hudo okvaro ledvic je malo; pri teh bolnikih je bila izpostavljenost alirokumabu približno 2-krat večja kot pri osebah z normalnim delovanjem ledvic.
English: A reduction of all-cause mortality was also observed, with only nominal statistical significance by hierarchical testing (HR 0.85, 95% CI: 0.73, 0.98).
Slovenian: Ugotovili so tudi zmanjšanje umrljivosti zaradi vseh vzrokov z nominalno statistično značilnostjo po hierarhičnem testiranju (HR 0,85, 95 % CI: 0,73, 0,98).
English: However, the LDLR has been shown to have a low affinity for Lp(a), therefore the exact mechanism by which alirocumab lowers Lp(a) is not fully understood.
Slovenian: Vendar ima LDLR majhno afiniteto za Lp(a), zato natančen mehanizem znižanja Lp(a) z alirokumabom ni povsem razjasnjen.
English: Praluent helps lower your levels of “bad” cholesterol (also called “LDL cholesterol”).
Slovenian: Zdravilo Praluent pomaga znižati koncentracijo "slabega" holesterola (ki ga imenujemo tudi "holesterol LDL").
English: Overall, 730 (7.7%) of 9451 patients switched to placebo.
Slovenian: V celoti je na placebo prešlo 730 (7,7 %) od 9451 bolnikov.
English: Click
Slovenian: klik
English: Combination therapy with a statin
Slovenian: Kombinirano zdravljenje s statinom
English: The absolute bioavailability of alirocumab after subcutaneous administration was about 85% as determined by population pharmacokinetic analysis.
Slovenian: Absolutna biološka uporabnost alirokumaba po subkutani uporabi je bila okrog 85 % (ugotovljeno s populacijsko farmakokinetično analizo).
English: Pharmacotherapeutic group: Other lipid modifying agents, ATC code: C10AX14.
Slovenian: Farmakoterapevtska skupina: Druga zdravila za spreminjanje ravni serumskih lipidov, Oznaka ATC: C10AX14.
English: EU/1/15/1031/001 EU/1/15/1031/002 EU/1/15/1031/003 EU/1/15/1031/004 EU/1/15/1031/005 EU/1/15/1031/006 EU/1/15/1031/007 EU/1/15/1031/008 EU/1/15/1031/009 EU/1/15/1031/010 EU/1/15/1031/011 EU/1/15/1031/012
Slovenian: EU/1/15/1031/002 EU/1/15/1031/003 EU/1/15/1031/004 EU/1/15/1031/005 EU/1/15/1031/006 EU/1/15/1031/007 EU/1/15/1031/008 EU/1/15/1031/009 EU/1/15/1031/010 EU/1/15/1031/011 EU/1/15/1031/012
English: When co-administered with a statin, the median apparent half-life of alirocumab was 12 days.
Slovenian: Med sočasno uporabo s statinom je bil mediani navidezni razpolovni čas alirokumaba 12 dni.
English: In the phase 3 studies, 31% of patients had type 2 diabetes mellitus, and 64% of patients had a history of coronary heart disease.
Slovenian: V študijah 3. faze je 31 % bolnikov imelo sladkorno bolezen tipa 2 in 64 % bolnikov je imelo anamnezo koronarne bolezni srca.
English: The patient may either self-inject Praluent, or a caregiver may administer Praluent, after guidance has been provided by a healthcare professional on proper subcutaneous injection technique.
Slovenian: Bolnik si lahko zdravilo Praluent injicira sam, ali mu ga injicira negovalec, potem ko oseba od zdravstvenega delavca dobi navodila o pravilnem načinu subkutanega injiciranja.
English: Overall, 71.6% of patients were categorized at high or very high CV risk and not at their LDL-C target.
Slovenian: V celoti je bilo 71,6 % bolnikov uvrščenih med bolnike z velikim ali zelo velikim srčno-žilnim tveganjem in niso dosegali svoje ciljne vrednosti h-LDL.
English: The offspring of monkeys that received high doses of alirocumab weekly throughout pregnancy had a weaker secondary immune response to antigen challenge than did the offspring of control animals.
Slovenian: Mladiči opic, ki so med brejostjo dobivale velike odmerke alirokumaba vsak teden, so imeli šibkejši sekundarni imunski odziv na provokacijo z antigenom kot mladiči kontrolnih živali.
English: • Adults with high cholesterol levels in their blood and with cardiovascular disease to reduce cardiovascular risk.
Slovenian: • Odrasli z visoko koncentracijo holesterola v krvi in s srčno-žilno boleznijo, za zmanjševanje tveganja srčno-žilnih dogodkov.
English: After removal from the refrigerator, the medicinal product must be used within 30 days or discarded.
Slovenian: Po odstranitvi iz hladilnika morate zdravilo v 30 dneh porabiti ali zavreči.
English: Praluent is not recommended during pregnancy or breast-feeding.
Slovenian: Zdravilo Praluent ni priporočljivo med nosečnostjo in obdobjem dojenja.
English: Mean changes for all other lipids/ lipoproteins were similar to the FH I and FH II studies, however statistical significance was not reached for TG, HDL-C and Apo A-1.
Slovenian: Povprečna sprememba vseh drugih lipidov/lipoproteinov je bila podobna kot v študijah FH I in FH II, vendar statistična značilnost ni bila dosežena za TG, HDL in Apo A-1.
English: • redness, itching, swelling, pain/tenderness where the medicine was injected (local injection site reactions)
Slovenian: • pordelost, srbenje, oteklost, bolečina/občutljivost na mestu injiciranja zdravila (lokalne reakcije na mestu injiciranja)
English: General allergic reactions were reported more frequently in the alirocumab group (8.1% of patients) than in the control group (7.0% of patients), mainly due to a difference in the incidence of pruritus.
Slovenian: Splošne alergijske reakcije so bile v skupini z alirokumabom opisane pogosteje (8,1 % bolnikov) kot v kontrolni skupini (7,0 % bolnikov), predvsem zaradi razlike v pogostnosti srbenja.
English: Following intravenous administration, the volume of distribution was about 0.04 to 0.05 L/kg indicating that alirocumab is distributed primarily in the circulatory system.
Slovenian: Po intravenski uporabi je volumen porazdelitve približno 0,04 do 0,05 l/kg; to kaže, da se alirokumab porazdeli predvsem v obtočilih.
English: • Check the liquid is clear, colourless to pale yellow and free from particles; if not, do not use.
Slovenian: • Preverite, da je tekočina bistra, brezbarvna do bledo rumena in da ne vsebuje delcev; če ni tako, je ne uporabite.
English: The discontinuation rate due to local injection site reactions was comparable between the two groups (0.2% in the alirocumab group versus 0.3% in the control group).
Slovenian: Delež prekinitev zaradi lokalnih reakcij na mestu injiciranja je bil med obema skupinama podoben (0,2 % v skupini z alirokumabom in 0,3 % v kontrolni skupini).
English: Driving and using machines This medicine is not expected to have any effect on your ability to drive or use machines.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Ni pričakovati, da bi to zdravilo vplivalo na sposobnost upravljanja vozil in strojev.
English:  Before you remove the needle check the syringe is empty.
Slovenian:  Preden izvlečete iglo, se prepričajte, da je brizga prazna.
English: • Hold the skin like this for the whole injection.
Slovenian: • Kožo med celotnim injiciranjem držite tako.
English: In animal studies, there were no adverse effects on surrogate markers of fertility (see section 5.3).
Slovenian: V študijah na živalih ni bilo neželenih učinkov na nadomestne označevalce plodnosti (glejte poglavje 5.3).
English: • Take the syringe out of the packaging by holding the syringe body.
Slovenian: • Vzemite brizgo iz pakiranja tako, da primete telo brizge.
English: Steady state was reached after 2 to 3 doses with an accumulation ratio up to a maximum of about 2-fold.
Slovenian: Stanje dinamičnega ravnovesja je bilo doseženo po 2 do 3 odmerkih, z največ približno 2-kratnim razmerjem kopičenja.
English: • Do not touch the yellow safety cover.
Slovenian: • Ne dotaknite se rumenega varnostnega ščitnika.
English: Hold the Praluent pen like this.
Slovenian: Držite peresnik zdravila Praluent tako.
English: Prior to initiating Praluent secondary causes of hyperlipidaemia or mixed dyslipidaemia (e.g., nephrotic syndrome, hypothyroidism) should be excluded.
Slovenian: Pred uvedbo zdravila Praluent je treba izključiti sekundarne vzroke hiperlipidemije ali mešane dislipidemije (npr. nefrotski sindrom, hipotiroidizem).